TY - JOUR
T1 - Design and synthesis of nitrate esters of aromatic heterocyclic compounds as pharmacological preconditioning agents
AU - Fotopoulou, Theano
AU - Iliodromitis, Efstathios K.
AU - Koufaki, Maria
AU - Tsotinis, Andrew
AU - Zoga, Anastasia
AU - Gizas, Vassilis
AU - Pyriochou, Anastasia
AU - Papapetropoulos, Andreas
AU - Andreadou, Ioanna
AU - Kremastinos, Dimitrios Th
PY - 2008/4/15
Y1 - 2008/4/15
N2 - Ischemic preconditioning (IPC) constitutes an endogenous protective mechanism in which one or more brief periods of myocardial ischemia and reperfusion render the myocardium resistant to a subsequent more-sustained ischemic insult. Pharmacological preconditioning represents an ideal alternative of IPC. We now describe the design and synthesis of indole, quinoline, and purine systems with an attached pharmacophoric nitrate ester group. The indole and quinoline derivatives 4 and 5 possess structural features of the nitrate containing KATP channel openers. Purine analogues 11 and 12, substituted at the position 6 by a piperidine moiety and at position 9 by an alkyl nitrate, could combine the effects of the nitrate containing KATP channel openers and those of adenosine. Compound 13 bears the nicotinamide moiety of nicorandil instead of nitrate ester. Compounds 4, 5, and 11 reduced infarction and the levels of malondialdehyde (MDA) at reperfusion in anesthetized rabbits. Compounds 12 and 13 did not significantly reduce the infarct size. Analogues 4 and 5 increased cGMP and MDA during ischemia, while combined analogue 4 and mitoKATP blocker 5-hydroxydecanoic acid (5-HD) abrogated this benefit suggesting an action through mitoKATP channel opening. Treatment with derivative 11 combined with 5-HD as well as treatment with 11 and adenosine receptor blocker 8-(p-sulfophenyl)theophylline (SPT) did not abrogate cardioprotection. Compound 11 is a lead molecule for the synthesis of novel analogues possessing a dual mode of action through cGMP-mitoKATP channel opening-free radicals and through adenosine receptors.
AB - Ischemic preconditioning (IPC) constitutes an endogenous protective mechanism in which one or more brief periods of myocardial ischemia and reperfusion render the myocardium resistant to a subsequent more-sustained ischemic insult. Pharmacological preconditioning represents an ideal alternative of IPC. We now describe the design and synthesis of indole, quinoline, and purine systems with an attached pharmacophoric nitrate ester group. The indole and quinoline derivatives 4 and 5 possess structural features of the nitrate containing KATP channel openers. Purine analogues 11 and 12, substituted at the position 6 by a piperidine moiety and at position 9 by an alkyl nitrate, could combine the effects of the nitrate containing KATP channel openers and those of adenosine. Compound 13 bears the nicotinamide moiety of nicorandil instead of nitrate ester. Compounds 4, 5, and 11 reduced infarction and the levels of malondialdehyde (MDA) at reperfusion in anesthetized rabbits. Compounds 12 and 13 did not significantly reduce the infarct size. Analogues 4 and 5 increased cGMP and MDA during ischemia, while combined analogue 4 and mitoKATP blocker 5-hydroxydecanoic acid (5-HD) abrogated this benefit suggesting an action through mitoKATP channel opening. Treatment with derivative 11 combined with 5-HD as well as treatment with 11 and adenosine receptor blocker 8-(p-sulfophenyl)theophylline (SPT) did not abrogate cardioprotection. Compound 11 is a lead molecule for the synthesis of novel analogues possessing a dual mode of action through cGMP-mitoKATP channel opening-free radicals and through adenosine receptors.
KW - Adenosine
KW - Infarct size
KW - K channel openers
KW - Pharmacological preconditioning
UR - http://www.scopus.com/inward/record.url?scp=42249094702&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=42249094702&partnerID=8YFLogxK
U2 - 10.1016/j.bmc.2008.02.051
DO - 10.1016/j.bmc.2008.02.051
M3 - Article
C2 - 18328715
AN - SCOPUS:42249094702
SN - 0968-0896
VL - 16
SP - 4523
EP - 4531
JO - Bioorganic and Medicinal Chemistry
JF - Bioorganic and Medicinal Chemistry
IS - 8
ER -